Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex' ranitidine

This article was originally published in The Tan Sheet

Executive Summary

ANDA for OTC 75 mg ranitidine tablets tentatively approved by FDA Sept. 29. Exclusivity for the reference drug, Warner-Lambert's Zantac 75, expires Dec. 19. The agency letter does not make reference to Apotex' petition to deny private label competitor Novopharm 180 days of exclusivity for its private label ranitidine product, which the company theoretically might receive as the first to file for the OTC drug ("The Tan Sheet" July 27, p. 15). Novopharm responded with a petition requesting the exclusivity award as well as the dismissal of Apotex' petition ("The Tan Sheet" Aug. 24, p. 8). FDA notes Apotex' certification that its "manufacture, use, sale or offer to sell" the product will not infringe on Zantac patents expiring in June 2002 and May 2008. Other firms with tentative approval include Chelsea and Ranbaxy
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel